About
Dr. Michael Scolaro, Founder, Chief Scientist Augustus BioTarget
Dr. Scolaro began research on targeted drug delivery with scientists Dr. Sean M. Sullivan, Ph.D., and Dr. Robert K. Gieseler, PhD. in 1989. Their first study was published in 1992 on inhibiting HIV-1 proliferation using liposome-encapsulated sense DNA: “Inhibition of HIV-1 Proliferation by Liposome Encapsulated Sense DNA to the 5’ tat Splice Acceptor Site” (Antisense Research and Development, vol. 2) 1992. Targeted Treatment of Neurodegenerative and Oncologic Diseases with Curcumin
This work provided the groundwork for his focus on targeted delivery of therapeutics begun at the 501 c 3 nonprofit foundation Let There Be Hope, and subsequently developed at Rodos BioTarget GmbH in Hannover, Germany (www.biotargeting.eu)
Establishing a clinical practice while also a Director of AIDS Research at the Los Angeles Oncologic Institute at St. Vincent Hospital, he dedicated his research to developing targeted treatments for people with HIV/AIDS, cancers, and allied disorders. The earlier focus on antiviral drug treatments expanded into targeted drug delivery and the invention of the CLR-TargoSphere® drug delivery technology with collaborators, Dr. Sean Sullivan and Dr. Robert Gieseler, currently being developed for targeted treatments to the brain for neurodegenerative diseases.
Joined
August 2017
